Pharmaceuticals

Royalty Pharma PLC - CL

Royalty Pharma PLC - CL released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 631 M (forecast USD 874.12 M), actual EPS USD 0.5296 (forecast USD 0.67)

Royalty Pharma Reports 21% Q1 EBITDA Growth and Raises Full-Year Revenue Guidance

Royalty Pharma PLC - CL to Release FY2026 Q1 Earnings on May 6, Pre-Market EST; Forecast Revenue USD 874.12 M, EPS USD 0.67

KBC Group NV reduces stake in Royalty Pharma PLC

Royalty Pharma Reaches $500M Research Agreement with Johnson & Johnson for Experimental Autoimmune Therapy

Royalty Pharma and Johnson & Johnson Reach $500 Million Joint Financing Agreement to Develop Autoimmune Disease Therapy

Royalty Pharma PLC - CL released FY2025 Q4 earnings on February 11 Pre-Market (EST), actual revenue USD 621.99 M (forecast USD 837.77 M), actual EPS USD 0.3852 (forecast USD 1.5)

Royalty Pharma PLC - CL released FY2025 Annual Earnings on February 11 Pre-Market (EST), Actual Revenue: USD 0 (Forecast: USD 3.217 B), Actual EPS: USD 0 (Forecast: USD 2.7725)

Royalty Pharma Reports Strong Earnings and Announces Share Repurchase

Royalty Pharma PLC - CL to release FY2025 Q4 earnings on February 11, Pre-Market EST, forecast revenue USD 837.77 M, EPS USD 1.5

Marshall Urist Sells Royalty Pharma Common Stock

Royalty Pharma PLC's CFO sells company stocks

Royalty Pharma to Release Business Update at JPM Healthcare Conference

Royalty Pharma announces 2025 revenue growth target

Teva Pharmaceuticals and Royalty Pharma Enter $500 Million Collaboration for TEV-408

Robeco Increases Holdings in Royalty Pharma

Citigroup Analyst Maintains Buy Rating on Royalty Pharma

Royalty Pharma Reaches New 52-Week High and Announces Dividend

Financiere Invests in Royalty Pharma, Stock Price Rises

Royalty Pharma Now Exclusively Owns 8% to 16% of Evrysdi Royalty Payments

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

RPRX

Commerzbank Aktiengesellschaft FI invested approximately $982,000 in Royalty Pharma PLC by purchasing 25,417 shares during the 4th quarter. Other institutional investors have also increased their stakes in the company. Analysts maintain a consensus 'Buy' rating for Royalty Pharma, with target prices ranging from $51.00 to $66.00. The stock opened at $52.85, with a market cap of $30.43 billion and a PE ratio of 35.95.

Market Beat

iShares US Pharma

Commerzbank AG

Goldman Sachs

Citigroup

Morgan Stanley

UBS Group AG

Zenas Biopharma

GS Hldg R

CITIGROUP INC 6.250 NON CUM SER II PFD WI

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX

LABU

SBIO

Royalty Pharma PLC (NASDAQ:RPRX) has received a consensus 'Buy' rating from seven brokerages. Analysts have set an average 1-year target price of $53.71. Recent upgrades include Morgan Stanley raising their target from $61 to $63 and Citigroup from $50 to $66. The company reported $1.30 EPS, exceeding estimates, and announced a quarterly dividend of $0.235 per share. Insider selling has occurred, with significant shares sold by Director Gregory Norden and CFO Terrance P. Coyne.

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

VG Health

Health Care Select Sector SPDR

Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts

Vidac Pharma Holding PLC is in advanced negotiations to join Quest for Health, a leading European life sciences accelerator in Strasbourg. This strategic expansion aims to enhance Vidac's integration within European biotechnology networks and improve access to partnerships and infrastructure. The company is also searching for a CEO to lead operations in Strasbourg. The decision regarding participation in Quest for Health and the executive appointment is expected by July 2026. CEO Dr. Max Herzberg emphasized the potential for scientific collaboration and operational growth through this initiative.

pressetext

The Company is in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg

Bank of America Securities has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $62.00. Analyst Jason Gerberry, a 5-star analyst with an 18.9% average return, highlights Royalty Pharma's Strong Buy consensus and a price target consensus of $59.43. Gerberry also covers other healthcare stocks like BioMarin Pharmaceutical and Ionis Pharmaceuticals.

Tip Ranks

Bank of America

BioMarin Pharma

Ionis Pharma

Alkermes

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TD Cowen analyst Michael Nedelcovych has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $50.00. The stock closed at $50.72. The analyst has an average return of -4.2% and a 41.67% success rate, focusing on the Healthcare sector. The consensus on Royalty Pharma is a Strong Buy, with an average price target of $54.17.

Bausch Health

Novo Nordisk AS

Royalty Pharma (RPRX) Gets a Buy from TD Cowen

Royalty Pharma plc (RPRX) reported a rise in Q1 earnings, with net income before tax increasing to $468 million from $434 million. Operating income also grew to $563 million from $534 million. Net income attributable to the company climbed to $295 million, while total income rose to $631 million. Income from financial royalty assets increased to $595 million. The company raised its full-year Portfolio Receipts outlook to between $3.325 billion and $3.450 billion, up from the previous estimate of $3.275 billion - $3.425 billion.

rttnews

Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook

RVMD

Royalty Pharma (NASDAQ:RPRX) reported strong Q1 2026 results, with a 10% growth in portfolio receipts and 13% in royalty receipts. The company announced $1.25 billion in transactions, repurchased 1 million shares for $50 million, and increased its dividend by 7%. Future guidance was raised, expecting full-year portfolio receipts between $3.325 billion and $3.45 billion. Positive clinical updates include Phase 3 results for Revolution Medicines and FDA approval of Denali's Avia. The company emphasized the importance of R&D co-funding and strategic investments in AI and the Asia Pacific region.

benzinga_article

Revolution Medicines

Teva Pharmaceutical Industries

Johnson & Johnson

Denali Therap

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Royalty Pharma plc reported Q1 2026 results with revenue of $630.58M, net income of $294.69M, and diluted EPS of $0.67, all showing year-over-year increases. Revenue grew by 11% due to new royalty acquisitions and stronger portfolio receipts, particularly in cystic fibrosis and Voranigo. The company deployed $527.9M in royalties and milestone payments and completed management internalization to enhance oversight. Upcoming regulatory and clinical catalysts are expected to impact future cash flows.

TradingView

Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary

Earnings Watch

Royalty Pharma PLC - CL | 8-K: FY2026 Q1 Revenue: USD 631 M

Royalty Pharma PLC - CL(RPRX.US)